RT Journal Article SR Electronic T1 How Important Are Study Designs? A Simulation Assessment of Vaccine Effectiveness Estimation Bias with Time-Varying Vaccine Coverage, and Heterogeneous Testing and Baseline Attack Rates JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2022.08.25.22279235 DO 10.1101/2022.08.25.22279235 A1 Suah, Jing Lian A1 Bar-Zeev, Naor A1 Knoll, Maria Deloria YR 2022 UL http://medrxiv.org/content/early/2022/08/30/2022.08.25.22279235.abstract AB Objective We studied how commonly used vaccine effectiveness (VE) study designs (variations of cohorts, and test-negative designs) perform under epidemiological nuances more prominent in the COVID-19 era, specifically time-varying vaccine coverage, and heterogeneous testing behaviour and baseline attack rates with selection on willingness to vaccinate.Methodology We simulated data from a multi-parameter conceptual model of the epidemiological environment using 888125 parameter sets. Four configurations of cohorts, and two test-negative designs, were conducted on the simulated data, from which estimation bias is computed. Finally, stratified and fixed effects linear regressions were estimated to quantify the sensitivity of estimation bias to model parameters.Findings Irrespective of study designs, dynamic vaccine coverage, and heterogeneous testing behaviour and baseline attack rates are important determinants of bias. Study design choices have non-trivial effects on VE estimation bias even if these factors are absent. The importance of these sources of bias differ across study designs.Conclusion A re-benchmarking of methodology, especially for studying COVID-19 VE, and implementation of vaccine-preventable disease surveillance systems that minimise these sources of bias, are warranted.HighlightsThis paper simulated a theoretical model with frictions in vaccination, testing, baseline disease risks, and heterogeneous vaccine effectiveness to evaluate estimation bias across four cohort and two test-negative designs.In theory, bias depends on behavioural asymmetries (in testing, and baseline risk) between the vax-willing and vax-unwilling, and the speed of vaccination rollout.There is intrinsic estimation bias across all study designs, with the direction and magnitude contingent on specific conditions.In scenarios that may be reflective of past SARS-CoV-2 waves, the degree of bias can be substantial, attributable to variation in assumed testing and baseline risk frictions.A regression-based decomposition indicates that study designs have visibly different primary sources of estimation bias, and degree of robustness in general.This study warrants a re-benchmarking of methodology and reporting checklists for VE research, and informs the design of cost-effective surveillance by quantifying part of the bias-implementation cost trade-off.Competing Interest StatementJLS received support for attending academic meetings from AstraZeneca for work outside the submitted work. NB-Z received research grants from Merck, personal fees from Merck, and a research grant from Johnson & Johnson, all for unrelated work outside the scope of this paper. MDK received reports grants from Merck, personal fees from Merck, and grants from Pfizer, outside the submitted work.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll scripts required for replication are available at github.com/suahjl/vemethod-simulation-frictions. http://github.com/suahjl/vemethod-simulation-frictions